Prospective Grant of Exclusive Commercialization License: The Use of Cysteamine for the Treatment of Pancreatic Cancer, Breast Cancer and Hepatocellular Cancer

摘要

This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, indicates that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive commercialization license to practice the inventions embodied in technology family E-219-2013/0, including U.S. patent application 61/ 814,010 entitled "A Novel Role of Cysteamine in Suppression of Cancer Invasion and Metastasis and Prolonging Survival of Host Through Inhibition of Matrix Metalloproteinases in Human Cancer" [HHS Ref. E- 219-2013/0-US-01], Canadian patent application 2,813,514 entitled "Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases" [HHS Ref. E-219-2013/0-CA-02], South Korean patent application 10-2013- 43713 entitled "Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases"[HHS Ref. E-219-2013/0-KR-03], Australian patent application 2013205350 entitled "Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases" [HHS Ref. E-219-2013/0-AU-04], and Mexican patent application MX/a/2013/004423 entitled "Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases" [HHS Ref. E-219-2013/0-MX-05]; and all related